Peptide Sciences Closed. Here Is What Researchers Need To Know.

// Market Update · Vendor Alternatives · Research Continuity · May 2026

One of the most recognized research peptide vendors in the United States shut down on March 6, 2026. Here is what happened, what it means for your research, and how to find a verified source you can rely on going forward.

What Happened to Peptide Sciences

On March 6, 2026, Peptide Sciences — one of the highest-traffic and most widely referenced research peptide vendors in the United States — posted a three-sentence notice on its homepage and went dark. No advance warning. No guidance for customers with pending orders. No explanation beyond the word “voluntary.”

The company was processing an estimated $7.4 million per month in sales at the time of closure, according to e-commerce analytics firm Grips Intelligence. For researchers who had relied on Peptide Sciences as a consistent source, the shutdown created an immediate problem — active research protocols suddenly had no supplier, and the market alternatives were unclear.

Any website currently claiming to be Peptide Sciences should be treated with extreme caution. The original company has ceased operations.

What Led to the Closure

While no official explanation was provided, publicly available industry reporting and regulatory records point to three converging forces that made continued operation untenable.

1. Escalating FDA enforcement activity. In the 18 months leading up to the shutdown, federal enforcement against gray-market research peptide vendors escalated dramatically. In December 2024, the FDA issued warning letters to Prime Peptides, Xcel Peptides, SwissChems, and Summit Research for selling unapproved drug products. By September 2025, more than 50 warning letters had gone out across the industry in a single month. The core regulatory argument was that selling compounds intended for injection — regardless of research-only labeling — constitutes selling unapproved drugs under the Federal Food, Drug, and Cosmetic Act.

2. The Amino Asylum raid. In June 2025, FDA agents conducted a physical warehouse raid on Amino Asylum’s facility in Memphis, Tennessee — the first physical raid on a major peptide vendor and a significant escalation from warning letters alone. Amino Asylum had been the second most recognized research peptide vendor in the United States. The site went offline within days. Peptide Sciences, widely considered the largest vendor in the market, saw what was coming.

3. Independent quality testing failures. Finnrick Analytics — an independent third-party testing platform — tested 37 samples of Peptide Sciences’ retatrutide and assigned an E rating, their lowest grade, across multiple batches. Independent quality failures of that scale, combined with accelerating regulatory pressure, represented a combination the business could not sustain.

4. Pharmaceutical litigation. Eli Lilly and Novo Nordisk — the patent holders behind tirzepatide and semaglutide respectively — pursued active legal action against gray-market GLP-1 suppliers. The International Trade Commission issued a General Exclusion Order blocking imports of infringing tirzepatide. For vendors carrying these compounds, the legal exposure became significant.

The Regulatory Landscape Right Now

The peptide industry is at an inflection point. On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of 19 previously restricted peptides would be moved back to Category 1 status — restoring legal access through licensed compounding pharmacies with a physician’s prescription. This is a significant development but it does not change the situation for research-use-only vendors. Compounded peptides still require a prescription and a licensed pharmacy. The FDA’s enforcement posture toward unlicensed research-use-only vendors has only intensified.

At the same time, the SAFE Drugs Act was introduced in early 2026, which would prohibit the sale of research chemicals identical to FDA-approved drugs without a New Drug Application. The legal runway for gray-market operations is narrowing.

What This Means for Researchers

If you sourced compounds from Peptide Sciences — whether for ongoing protocols, long-term studies, or regular procurement — the immediate challenge is finding a replacement that meets the same or higher documentation standards.

The gray market has never had a shortage of vendors making quality claims. What it has always lacked is vendors who can verify those claims with independent, documented evidence. The closure of Peptide Sciences, combined with the earlier closure of Amino Asylum, has concentrated demand into a smaller pool of remaining vendors. Not all of them meet research-grade documentation standards. Knowing what to look for before you order is the most important thing you can do to protect the integrity of your research.

What to Look for in a Replacement Supplier

Batch-specific COA with HPLC chromatogram. A purity percentage alone is not sufficient. The actual chromatograph showing the purity peak must be present on every COA. Generic COAs applied across multiple batches are a significant red flag.

Mass spectrometry identity confirmation. HPLC purity confirms the compound is pure — it does not confirm you have the right compound. LC-MS or ESI-MS identity confirmation is required to verify molecular weight matches the intended sequence.

Independent third-party laboratory. A COA issued by the manufacturer’s own in-house lab has an inherent conflict of interest. Look for ISO/IEC 17025 accredited laboratories — the international standard for testing and calibration. The lab name and accreditation should be clearly stated on every COA.

COA accessible before purchase. You should be able to review documentation before placing an order. Pre-purchase COA access is a sign of a supplier confident in their product.

Consistent batch numbering and traceability. Every vial should carry a batch number that corresponds directly to the COA you received. If you cannot trace your product back to specific test results you cannot verify what you have.

Clean research-use-only compliance. The vendor’s website, product descriptions, and all communications should maintain consistent research-only language. Inconsistent compliance language is a warning sign that the vendor’s legal positioning is weak.

What Titanborn Research Offers Researchers Transitioning from Peptide Sciences

Titanborn Research was built around the exact problem the Peptide Sciences closure illustrates — the need for a research peptide source that prioritizes verified quality and full documentation above everything else.

99%+ minimum purity — enforced, not claimed. Every batch must meet a strict 99%+ minimum purity standard before it enters our inventory. Batches that do not meet this threshold are refused. No exceptions.

USA-based independent third-party testing. Every product is independently tested by Vanguard Laboratory — an ISO/IEC 17025:2017 accredited, A2LA certified U.S. laboratory based in Olympia, Washington. Certificate of Analysis results are hosted directly on Vanguard’s servers and accessible via QR code on every vial. You are not verifying our claim — you are verifying the lab’s independent result.

Batch-specific COA with every order. Every order ships with a batch-specific Certificate of Analysis including HPLC purity analysis, LC-MS identity confirmation, endotoxin testing, sterility, and heavy metals screening. The batch number on your vial matches the COA in your documentation.

Clean compliance positioning. Titanborn Research is a registered U.S. LLC operating for research use only. Our legal pages, product descriptions, shipping documentation, and all customer communications maintain consistent research-only language throughout.

A real company with real accountability. Veteran owned and operated. There is a real person behind this business — not an anonymous operation. We stand behind every order we ship.